0001209191-20-032794.txt : 20200528
0001209191-20-032794.hdr.sgml : 20200528
20200528202634
ACCESSION NUMBER: 0001209191-20-032794
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200516
FILED AS OF DATE: 20200528
DATE AS OF CHANGE: 20200528
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DENYES NANCY
CENTRAL INDEX KEY: 0001640869
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 20923688
MAIL ADDRESS:
STREET 1: C/O ATYR PHARMA, INC.
STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Krueger Nancy
DATE OF NAME CHANGE: 20150429
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-731-8389
MAIL ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-16
0
0001339970
aTYR PHARMA INC
LIFE
0001640869
DENYES NANCY
3545 JOHN HOPKINS COURT, SUITE 250
SAN DIEGO
CA
92121
0
1
0
0
General Counsel
Common Stock
2020-05-16
4
M
0
892
A
3057
D
Common Stock
2020-05-20
4
S
0
322
3.62
D
2735
D
Employee Stock Option (right to buy)
4.06
2020-05-26
4
A
0
30000
0.00
A
2030-05-26
Common Stock
30000
30000
D
Restricted Stock Unit
2020-05-16
4
M
0
892
0.00
D
Common Stock
892
0
D
Restricted stock units (RSU) convert into common stock on a one-for-one basis.
Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2020.
Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on May 16, 2018.
50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020.
The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on May 16, 2019.
Nancy E. Denyes
2020-05-28